Circulating and in situ lymphocyte subsets and Langerhans cells in patients with compositae oleoresin dermatitis and increased ultraviolet A sensitivity during treatment with azathioprine.
Circulating and in situ lymphocyte subsets and Langerhans cells in four patients with compositae oleoresin dermatitis and increased ultraviolet A sensitivity before and during treatment with azathioprine were estimated. It was found that the number of Leu 6+ Langerhans cells decreased during therapy. This decrease was accompanied by a reduction in the number of Leu 2a+, Leu 3a+, Leu 4+, DR+, and Leu M2+ cells in the blood and a reduction in the number of Leu 2a+, Leu 3a+, Leu 4+, and DR+ cells in the skin. Concomitantly with the changes in the number of immunocompetent cells, the eczema cleared.
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use*; D002452:Cell Count; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007801:Langerhans Cells / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010787:Photosensitivity Disorders / Q000188:drug therapy* / Q000276:immunology; D010936:Plant Extracts / Q000009:adverse effects*; D012867:Skin / Q000276:immunology; D013601:T-Lymphocytes / Q000145:classification* / Q000276:immunology; D014466:Ultraviolet Rays / Q000009:adverse effects*
D010936:Plant Extracts; C018620:oleoresins; D001379:Azathioprine